Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused biotechnology company developing therapies designed to reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the closing of its approximately $40 million underwritten public offering.
The offering consisted of American Depositary Shares (“ADSs”), each representing 500 ordinary shares, or pre-funded warrants in lieu thereof, together with accompanying Series A and Series B Warrants. The securities were offered at a combined public offering price of $15.50 per ADS and accompanying warrants, resulting in expected gross proceeds of approximately $40 million, before deducting underwriting discounts, commissions and offering expenses. If the Series A and Series B Warrants are exercised in full, Kazia could receive approximately $80 million in additional gross proceeds.
Leerink Partners and Guggenheim Securities acted as joint book-running managers for the offering. BTIG and Needham & Company acted as lead managers, and Laidlaw & Company (UK) Ltd. acted as co-manager.
Lucosky Brookman LLP served as legal counsel to Kazia Therapeutics Limited in connection with the underwritten public offering.
